Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ELTX | PRESS-RELEASE | neutral | 5/10 | Elicio Therapeutics reported its 2025 financial results and provided updates on its Phase 2 AMPLIFY-7P trial for ELI-002 | Mar 12, 2026 |
| ALLO | PRESS-RELEASE | neutral | 5/10 | Allogene Therapeutics reported Q4 and full-year 2025 financial results, highlighting a reduced net loss compared to the | Mar 12, 2026 |
| XENE | PRESS-RELEASE | neutral | 5/10 | Xenon Pharmaceuticals closed a public offering of 12,236,843 common shares and pre-funded warrants to purchase 877,194 a | Mar 12, 2026 |
| DNTH | PRESS-RELEASE | neutral | 6/10 | Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering of 8.47 million comm | Mar 12, 2026 |
| CRVS | PRESS-RELEASE | bullish | 8/10 | Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic derm | Mar 12, 2026 |
| CAPR | PRESS-RELEASE | mixed | 6/10 | Capricor Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $31 | Mar 12, 2026 |
| INAB | PRESS-RELEASE | bullish | 8/10 | IN8bio reported strong clinical data in glioblastoma showing a 97% improvement in median progression-free survival with | Mar 12, 2026 |
| ERAS | PRESS-RELEASE | mixed | 6/10 | Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash | Mar 12, 2026 |
| MOLN | PRESS-RELEASE | mixed | 6/10 | Molecular Partners reported its 2025 financial results and provided updates on its clinical pipeline, including the init | Mar 12, 2026 |
| SLS | PRESS-RELEASE | bullish | 7/10 | SELLAS Life Sciences has enrolled the first patient in a Phase 2 trial for its CDK9 inhibitor SLS009 (tambiciclib) in ne | Mar 12, 2026 |
| CELU | PRESS-RELEASE | mixed | 6/10 | Celularity Inc. announced a strategic commercialization partnership with NEXGEL, Inc., licensing its established biomate | Mar 12, 2026 |
| CADL | PRESS-RELEASE | mixed | 6/10 | Candel Therapeutics reported Q4 and full-year 2025 financial results, highlighting a significant increase in R&D and ope | Mar 12, 2026 |
| CLNN | PRESS-RELEASE | mixed | 7/10 | Clene Inc. reported its 2025 financial results, highlighted by a 33% reduction in net loss to $26.2 million and an overs | Mar 12, 2026 |
| TOVX | PRESS-RELEASE | mixed | 6/10 | Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tie | Mar 12, 2026 |
| FLNA | PRESS-RELEASE | bearish | 7/10 | Filana Therapeutics reported a significantly wider net loss of $91.0 million in 2025 compared to $24.3 million in 2024, | Mar 12, 2026 |
| IPSC | PRESS-RELEASE | bullish | 8/10 | Century Therapeutics reported full-year 2025 financial results, highlighted by a significant reduction in net loss to $9 | Mar 12, 2026 |
| MBX | PRESS-RELEASE | neutral | 5/10 | MBX Biosciences reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balance sheet with $ | Mar 12, 2026 |
| DARE | PRESS-RELEASE | bullish | 7/10 | Daré Bioscience announced FDA clearance of the IND application for its planned Phase 2 clinical trial of DARE-HPV, a pot | Mar 12, 2026 |
| IXHL | PRESS-RELEASE | bullish | 8/10 | Incannex Healthcare announced statistically significant Phase 2 results for its lead drug candidate IHL-42X in obstructi | Mar 12, 2026 |
| CVKD | PRESS-RELEASE | mixed | 6/10 | Cadrenal Therapeutics released preclinical data showing its 12-LOX inhibitor, CAD-1005, may have therapeutic benefits in | Mar 12, 2026 |
| AMTX | PRESS-RELEASE | mixed | 6/10 | Aemetis reported Q4 and full-year 2025 results with improved quarterly performance driven by strong biogas growth and lo | Mar 12, 2026 |
| SPRC | PRESS-RELEASE | mixed | 5/10 | SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs, has advanced its collaboration with Clearmi | Mar 12, 2026 |
| IFRX | PRESS-RELEASE | neutral | 3/10 | InflaRx N.V. announced it will release its Q4 and full-year 2025 financial and operating results on March 19, 2026, befo | Mar 12, 2026 |
| HBIO | 8-K, PRESS-RELEASE | mixed | 6/10 | Harvard Bioscience reported full-year 2025 revenue of $86.6M, down from $94.1M in 2024, driven by a challenging market a | Mar 12, 2026 |
| MCRB | PRESS-RELEASE | mixed | 6/10 | Seres Therapeutics reported a net income of $5.7 million from continuing operations in 2025, a significant improvement f | Mar 12, 2026 |
| PRQR | PRESS-RELEASE | mixed | 6/10 | ProQR Therapeutics reported its 2025 financial results and provided a business update, highlighting advancement of its A | Mar 12, 2026 |
| RLMD | PRESS-RELEASE | neutral | 3/10 | Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 f | Mar 12, 2026 |
| XOMA | PRESS-RELEASE | neutral | 3/10 | XOMA Royalty Corporation announced it will report its fourth quarter and full year 2025 financial results on March 18, 2 | Mar 12, 2026 |
| GYRE | PRESS-RELEASE | mixed | 6/10 | Gyre Therapeutics reported solid full-year 2025 revenue growth of 10.2% to $116.6 million, driven by new product launche | Mar 12, 2026 |
| PCRX | PRESS-RELEASE | neutral | 4/10 | Pacira BioSciences responded to an activist investor, DOMA Perpetual Capital Management, which has nominated three direc | Mar 11, 2026 |